Assess whether to resubmit, meet, or pause the program (65c135)

SITUATION Complete-response-letter deficiency list arrived with a site-change that invalidates stability claims for pediatric-plan strategist; this Pharma & Life Sciences CMC and Development Pathways close is to resubmit, meet, or in a company with a CMC site change mid-review. That is a Pharma & Life Sciences CMC and Development Pathways decision on to resubmit, meet, or in a company with a CMC site change mid-review.

DECISION Pediatric-plan strategist in a company with a CMC site change mid-review must choose To resubmit, meet, / Pause the program using complete-response-letter deficiency list after a site-change that invalidates stability claims.

HYPOTHESES TO TEST 1. The population in complete-response-letter deficiency list is the one a site-change that invalidates stability claims named, so To resubmit, meet, follows for this CMC and Development Pathways file. 2. The population in complete-response-letter deficiency list is adjacent only to a site-change that invalidates stability claims; Pause the program is the honest Pharma & Life Sciences call. 3. A company with a CMC site change mid-review already contained a site-change that invalidates stability claims before complete-response-letter deficiency list arrived; no new CMC and Development Pathways path. 4. Provenance on complete-response-letter deficiency list after a site-change that invalidates stability claims is broken; do not pick To resubmit, meet, or Pause the program yet.

ANALYSIS REQUIRED 1. Map FDA-response timing and owner in a company with a CMC site change mid-review. 2. Trace CMC, labeling, or pharmacovigilance facts in complete-response-letter deficiency list after a site-change that invalidates stability claims. 3. Separate an isolated adverse event from a systemic quality issue. 4. For this Pharma & Life Sciences CMC and Development Pathways file, read complete-response-letter deficiency list against a site-change that invalidates stability claims and write the one fact that would move to resubmit, meet, or for pediatric-plan strategist.

RECOMMENDATION Choose To resubmit, meet, / Pause the program on this Pharma & Life Sciences / CMC and Development Pathways packet (complete-response-letter deficiency list after a site-change that invalidates stability claims). If complete-response-letter deficiency list cannot force a Pharma & Life Sciences label under CMC and Development Pathways, stop. If complete-response-letter deficiency list after a site-change that invalidates stability claims cannot support To resubmit, meet, versus Pause the program on this Pharma & Life Sciences CMC and Development Pathways close, pediatric-plan strategist must state the unresolved clinical or safety evidence requirement explicitly.